Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 5Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 87Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 42Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27Paclitaxel 27atezolizumab 26Ipilimumab 26Cisplatin 23Radiation 22Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 16130-nm albumin-bound paclitaxel 16palbociclib 15Decitabine 15Cytarabine 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × anetumab ravtansine × Clear all
NCT03816358 2026-05-13

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡